Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Down 19.1% in July

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totalling 12,300 shares, a decline of 19.1% from the July 15th total of 15,200 shares. Based on an average trading volume of 5,700 shares, the short-interest ratio is currently 2.2 days. Currently, 0.9% of the company’s shares are short sold.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC increased its stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,570 shares of the company’s stock after purchasing an additional 3,170 shares during the period. Aaron Wealth Advisors LLC owned approximately 1.45% of Creative Medical Technology worth $75,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Stock Performance

NASDAQ:CELZ traded up $0.04 on Friday, reaching $3.50. The company’s stock had a trading volume of 8,138 shares, compared to its average volume of 86,732. Creative Medical Technology has a 1-year low of $2.90 and a 1-year high of $10.28. The business’s 50-day moving average price is $3.60 and its two-hundred day moving average price is $4.34. The firm has a market cap of $4.72 million, a PE ratio of -0.94 and a beta of 2.11.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.27). The company had revenue of $0.01 million during the quarter. As a group, sell-side analysts expect that Creative Medical Technology will post -3.29 EPS for the current year.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.